The discontinuation is voluntary and is not related to product quality, safety or efficacy.
Patients with rheumatoid arthritis with chronic hepatitis B virus infection demonstrated greater radiographic progression and poorer clinical response at 1 year.
Low screening rate seen at same time as increase in hepatitis C virus prevalence among pregnant women.
Sofosbuvir-based treatment appears to guarantee renal safety for patients with chronic hepatitis C virus over one year of follow-up.
Methadone Maintenance Therapy Associated With Greater Access to Physician Care in HCV-Positive Drug UsersMay 10, 2018
The investigators suggest that enrollment in a methadone maintenance therapy program may be helpful in providing access to HCV care in people who inject drugs.
The authors examined data from 8887 individuals who began TNF antagonist treatment for an autoimmune disease from 2001 through 2010 and were followed through 2012; 52% of these patients were screened for HBV before treatment.
A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.
In this retrospective study, only a fraction of infants receiving well-child care at the study institution were screened for hepatitis C, despite being born to mothers with a known history of hepatitis C virus infection.
Findings highlight the importance of screening for metabolic syndrome (MS) and the potential for MS to influence alanine aminotransferase and its interpretation in the context of HBV treatment decisions.
The CDC has published ACIP recommendations regarding the use of Heplisav-B.
Study results support the indication of glecaprevir/pibrentasvir as the first 8-week pangenotypic treatment option for HCV/HIV-1 coinfected patients without cirrhosis.
Katie Burk, MPH, presented measures undertaken by the city of San Francisco to provide integrated responses to the concurrent HIV/HCV and opioid public health epidemics.
Maternal use of tenofovir disoproxil fumarate does not lower hepatitis B virus transmission rates.
For patients with chronic HBV, BMI is significantly associated with increased risk of hepatocellular carcinoma.
Future research should develop interventions to increase HCV screening with special focus on groups demonstrating significantly lower screening rates, such as Hispanics and women.
Alcohol dependence has deleterious effects on frontal cortical volumes that are compounded by hepatitis C virus infection and drug dependence.
HCV eradication by DAA improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.
Hepatitis B e-antigen positive mothers receiving tenofovir daily from 28-weeks gestation to 2 months postpartum did not show significant reductions in HBV transmission rates compared to placebo treated participants.
No HCV infection was detected in patients receiving HCV-infected kidneys 12 weeks following treatment.
The FDA approval of Heplisav-B was based on data from 3 phase 3 noninferiority trials involving close to 10,000 adults who received the vaccine.
A case of remission of psoriasis after treatment of chronic hepatitis C virus has been described.
The Advisory Committee on Immunization Practices has issued updated recommendations for HBV prevention.
Dynavax Technologies announced the availability of a two-dose hepatitis B vaccine for adults.
Reduced DAA delays and denials for patients with HCV reduced with provider-pharmacy collaboration.
More than one-third of adult US HIV patients miss opportunities to initiate hepatitis B vaccination.
State medical surveillance data suggest that the risk for mother-to-infant vertical transmission of hepatitis C virus is increasing.
Experts discuss the management of drug-drug interactions in patients receiving treatment for HIV and HCV coinfection.
Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin demonstrated high rates of adherence and SVR in different HCV patient subgroups, including patients with advanced fibrosis combined with chronic comorbidities.
Investigators evaluated whether unfavorable outcomes were prevented once sustained virologic response was achieved in older adults with HCV.
Safety and efficacy of sofosbuvir plus grazoprevir/elbasvir plus ribavirin was evaluated in individuals who did not achieve sustained virological response on NS5A or NS3-based therapy and RAS failure.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Importance of PrEP for People Involved in Criminal Justice Systems
- Increasing Incidence of Syphilis in People With HIV
- FDA: Possible Risk of Neural Tube Birth Defects With Certain Antiretroviral Agents
- Fungal Infections of the CNS: Diagnostic and Treatment Approaches
- Study Supports Development of a Vaccine for Recurrent Vulvovaginal Candidiasis
- Early Flow Cytometry Predictive of Clinical Deterioration in Sepsis
- Could a New Universal Tuberculosis Regimen Help End the TB Pandemic?
- Hepatitis C Virus Infection Linked to Gut Dysbiosis
- Two Hepatitis C Virus Infection Treatments to Be Discontinued
- Antibiotic Use During Pregnancy May Increase Risk for Childhood Asthma